{"transactions":[{"id":1503788,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":90663,"kind":"person","name":"Oakes Gregory","position":1,"cik":"0001809796","reported_name":"Oakes Gregory","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-05-23T17:45:09.000Z","date":"2024-05-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":167724,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agmt, by and among the Issuer, Guarantor, Parent and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, at the Effective Time, this  option was canceled and converted into the right to receive (a) a cash amount equal to  (1) the number of shares underlying this  option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this  option, plus (b) one CVR representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agmt, by and among the Issuer, Guarantor, Parent and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, at the Effective Time, this  option was canceled and converted into the right to receive (a) a cash amount equal to  (1) the number of shares underlying this  option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this  option, plus (b) one CVR representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agmt, by and among the Issuer, Guarantor, Parent and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, at the Effective Time, this  option was canceled and converted into the right to receive (a) a cash amount equal to  (1) the number of shares underlying this  option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this  option, plus (b) one CVR representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":7.9,"underlying":"Common Stock","underlying_shares":167724},"source":{"system":"sec-edgar","filing":"0001415889-24-014334","document":"form4-05232024_050501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1809796/000141588924014334/form4-05232024_050501.xml","form_type":"4"}},{"id":1503787,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":90663,"kind":"person","name":"Oakes Gregory","position":1,"cik":"0001809796","reported_name":"Oakes Gregory","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-05-23T17:45:09.000Z","date":"2024-05-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":47529,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agmt, by and among the Issuer, Guarantor, Parent and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, at the Effective Time, this  option was canceled and converted into the right to receive (a) a cash amount equal to  (1) the number of shares underlying this  option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this  option, plus (b) one CVR representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agmt, by and among the Issuer, Guarantor, Parent and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, at the Effective Time, this  option was canceled and converted into the right to receive (a) a cash amount equal to  (1) the number of shares underlying this  option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this  option, plus (b) one CVR representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agmt, by and among the Issuer, Guarantor, Parent and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, at the Effective Time, this  option was canceled and converted into the right to receive (a) a cash amount equal to  (1) the number of shares underlying this  option at the Effective Time multiplied by (2) an amount equal to (A) $20.42 less (B) the exercise price of this  option, plus (b) one CVR representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each share underlying this option at the Effective Time, without interest and subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":3.7,"underlying":"Common Stock","underlying_shares":47529},"source":{"system":"sec-edgar","filing":"0001415889-24-014334","document":"form4-05232024_050501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1809796/000141588924014334/form4-05232024_050501.xml","form_type":"4"}},{"id":1503786,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":90663,"kind":"person","name":"Oakes Gregory","position":1,"cik":"0001809796","reported_name":"Oakes Gregory","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-05-23T17:45:09.000Z","date":"2024-05-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":54454,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the right to receive one share of Landos Biopharma, Inc., common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 (\"Merger Agmt\"), by and among the Issuer, AbbVie Inc. (\"Guarantor\"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor (\"Parent\") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger(\"Effective Time\"), each RSU held by the Reporting Person was canceled and converted into the right to receive (a) acash amount equal to $20.42 multiplied by the aggregate number of unvested and outstanding RSUs as of immediately prior to the Effective Time, plus (b) one contractual contingent value right (\"CVR\") representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each unvested and outstanding RSU, without interest and subject to any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 (\"Merger Agmt\"), by and among the Issuer, AbbVie Inc. (\"Guarantor\"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor (\"Parent\") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger(\"Effective Time\"), each RSU held by the Reporting Person was canceled and converted into the right to receive (a) acash amount equal to $20.42 multiplied by the aggregate number of unvested and outstanding RSUs as of immediately prior to the Effective Time, plus (b) one contractual contingent value right (\"CVR\") representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each unvested and outstanding RSU, without interest and subject to any applicable withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated 3/24/2024 (\"Merger Agmt\"), by and among the Issuer, AbbVie Inc. (\"Guarantor\"), Bespin Subsidiary, LLC, a wholly owned subsidiary of Guarantor (\"Parent\") and Bespin Merger Sub, Inc. a wholly owned subsidiary of Parent, immediately prior to the effective time of the merger(\"Effective Time\"), each RSU held by the Reporting Person was canceled and converted into the right to receive (a) acash amount equal to $20.42 multiplied by the aggregate number of unvested and outstanding RSUs as of immediately prior to the Effective Time, plus (b) one contractual contingent value right (\"CVR\") representing the right to receive a contingent payment of $11.14 in cash upon the achievement of a specified milestone as set forth in the Contingent Value Rights Agreement (as defined in the Merger Agmt), for each unvested and outstanding RSU, without interest and subject to any applicable withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":54454},"source":{"system":"sec-edgar","filing":"0001415889-24-014334","document":"form4-05232024_050501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809796/000141588924014334/form4-05232024_050501.xml","form_type":"4"}},{"id":1603429,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":90663,"kind":"person","name":"Oakes Gregory","position":1,"cik":"0001809796","reported_name":"Oakes Gregory","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-03-04T16:06:34.000Z","date":"2024-02-29","kind":"grant","planned":false,"acquired":true,"shares":54454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of Landos Biopharma, Inc., Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Stock Unit (\"RSU\") shall vest as to 66 2/3% of the shares underlying the RSU on the second anniversary of the date of grant and\nshall vest as to 33 1/3% of the shares underlying the RSU on the third anniversary of the date of grant, subject to the Reporting Person's\ncontinuous service with the Issuer on each such date."}],"balance_after":54454,"derivative":{"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":54454},"source":{"system":"sec-edgar","filing":"0001209191-24-004208","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809796/000120919124004208/doc4.xml","form_type":"4"}},{"id":1979840,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":90663,"kind":"person","name":"Oakes Gregory","position":1,"cik":"0001809796","reported_name":"Oakes Gregory","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-02T16:13:17.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":475300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares initially subject to the option shall vest on the one (1) year anniversary of the date of grant (such anniversary being the \"Anniversary Date\") and 1/48th of the shares initially subject to the option shall vest on each monthly anniversary of the Anniversary Date thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date."}],"balance_after":475300,"derivative":{"exercise_price":0.37,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":475300},"source":{"system":"sec-edgar","filing":"0001209191-23-014626","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809796/000120919123014626/doc4.xml","form_type":"4"}},{"id":2224256,"issuer":{"id":90644,"kind":"organization","name":"Landos Biopharma, Inc.","symbol":"LABP"},"owners":[{"id":90663,"kind":"person","name":"Oakes Gregory","position":1,"cik":"0001809796","reported_name":"Oakes Gregory","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-06-22T16:28:48.000Z","date":"2022-06-20","kind":"grant","acquired":true,"shares":1677251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares of common stock underlying this option will vest and become exercisable on June 20, 2023 and the remaining shares of common stock underlying this option will vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date."}],"balance_after":1677251,"derivative":{"exercise_price":0.79,"expiration_date":"2032-06-19","underlying":"Common Stock","underlying_shares":1677251},"source":{"system":"sec-edgar","filing":"0001209191-22-038682","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809796/000120919122038682/doc4.xml","form_type":"4"}},{"id":2454496,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":90663,"kind":"person","name":"Oakes Gregory","position":1,"cik":"0001809796","reported_name":"Oakes Gregory","relationship":{"director":true}}],"security":"Stock option (right to buy)","published_at":"2022-01-03T21:07:12.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":34482,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal quarterly installments on each of March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022."}],"balance_after":34482,"derivative":{"exercise_price":1.45,"expiration_date":"2032-01-03","underlying":"Common stock, par value $0.0001 per share","underlying_shares":34482},"source":{"system":"sec-edgar","filing":"0001140361-22-000299","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809796/000114036122000299/form4.xml","form_type":"4"}},{"id":2916202,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":90663,"kind":"person","name":"Oakes Gregory","position":1,"cik":"0001809796","reported_name":"Oakes Gregory","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options (right to buy)","published_at":"2021-01-06T21:48:35.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":41237,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in equal quarterly installments on each of March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021."}],"balance_after":41237,"derivative":{"exercise_price":0.97,"expiration_date":"2031-01-03","underlying":"Common stock, par value $0.0001 per share","underlying_shares":41237},"source":{"system":"sec-edgar","filing":"0001415889-21-000255","document":"form4-01062021_060128.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809796/000141588921000255/form4-01062021_060128.xml","form_type":"4"}},{"id":3175760,"issuer":{"id":7534,"kind":"organization","name":"GridAI Technologies Corp.","symbol":"GRDX"},"owners":[{"id":90663,"kind":"person","name":"Oakes Gregory","position":1,"cik":"0001809796","reported_name":"Oakes Gregory","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2020-04-16T21:51:42.000Z","date":"2020-04-13","kind":"grant","acquired":true,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Options granted in connection with the Reporting Person's appointment as a director to serve on the Board of the Issuer for the remainder of the fiscal year ending December 31, 2020 pursuant to the Issuer's 2014 Omnibus Equity Incentive Plan. The options vest in three equal installments on each of June 30, 2020, September 30, 2020, and December 31, 2020, in accordance with the Issuer's Director Compensation Plan (\"Plan\").  The Plan provides for the grant to each independent director of options to purchase 80,000 shares of common stock for service on the Board during the fiscal year ending December 31, 2020, which vest ratably each quarter during the fiscal year.  The exercise price was determined based on the higher of the last price paid for shares of the Issuer's common stock or the fair market value of Issuer's common stock on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted in connection with the Reporting Person's appointment as a director to serve on the Board of the Issuer for the remainder of the fiscal year ending December 31, 2020 pursuant to the Issuer's 2014 Omnibus Equity Incentive Plan. The options vest in three equal installments on each of June 30, 2020, September 30, 2020, and December 31, 2020, in accordance with the Issuer's Director Compensation Plan (\"Plan\").  The Plan provides for the grant to each independent director of options to purchase 80,000 shares of common stock for service on the Board during the fiscal year ending December 31, 2020, which vest ratably each quarter during the fiscal year.  The exercise price was determined based on the higher of the last price paid for shares of the Issuer's common stock or the fair market value of Issuer's common stock on the date of grant."}],"balance_after":60000,"derivative":{"exercise_price":0.97,"expiration_date":"2030-04-13","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-20-001020","document":"form4-04162020_060431.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809796/000141588920001020/form4-04162020_060431.xml","form_type":"4"}}]}